Seeking Alpha

Mike Zaman's  Instablog

Mike Zaman
Send Message
  • Wall Street's Augury: Receptos Inc (Nasdaq:RCPT) 0 comments
    Jun 9, 2014 6:46 PM | about stocks: RCPT

    http://static.cdn-seekingalpha.com/uploads/2014/5/25/saupload_crwe_pr_finance_wall_street.jpg

    http://static.cdn-seekingalpha.com/uploads/2014/6/9/saupload_rcpt.jpg Receptos, Inc. (NASDAQ:RCPT)

    Multiple sclerosis (NYSE:MS) is an autoimmune disease that affects the central nervous system. With multiple sclerosis, the brain has difficulty getting messages to the rest of the body.

    MS can cause a variety of symptoms, including changes in sensation (hypoesthesia), muscle weakness, abnormal muscle spasms, or difficulty in moving; difficulties with coordination and balance (ataxia); problems in speech (dysarthria) or swallowing (dysphagia), visual problems (nystagmus, optic neuritis, or diplopia), fatigue and acute or chronic pain syndromes, bladder and bowel difficulties, cognitive impairment, or emotional symptomatology (mainly depression).

    Statistics indicate that there are currently 350,000 to 500,000 people in the U.S. who have been diagnosed with MS. Two hundred people are diagnosed with MS every week and over 2.5 million people are living with the disease worldwide. MS is most commonly diagnosed in individuals between the ages of 20 and 50, although it can develop in young children and teens as well as older adults. The disease is twice as common in women as in men.

    Multiple sclerosis relapses are often unpredictable and can occur without warning with no obvious inciting factors.

    After the closing bell on Monday, RCPT reported that the Phase 2 portion of the RADIANCE trial of its selective S1P1 receptor modulator, RPC1063, in relapsing multiple sclerosis (RMS) met the primary endpoint, reduction in MRI (magnetic resonance imaging) brain lesion activity.

    The overall safety profile of RPC1063 was consistent with the results of prior trials, and continues to support the differentiation of the drug candidate against other oral agents for treatment of RMS on the market or in clinical development.

    RCPT's RPC1063 is a sphingosine 1-phosphate 1 receptor (S1P1R) small molecule modulator candidate for immune indications, including relapsing multiple sclerosis and inflammatory bowel disease.

    http://static.cdn-seekingalpha.com/uploads/2014/6/9/saupload_rcptch.png

    RCPT is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases.

    More about Receptos, Inc. (RCPT) at www.receptos.com

    **

    Read Full Disclaimer at www.finance.crwe-pr.com/disclaimer

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Back To Mike Zaman's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.